Christine E. Marx

TL;DR: A brief review and critique of the current therapeutic armamentarium for treating schizophrenia and drug development strategies and theories of mechanisms of action of antipsychotic drugs is provided, and focuses on novel targets for therapeutic agents for future drug development.

TL;DR: A review of the current literature describing preclinical and clinical studies that evaluate the efficacy of antipsychotic drugs, their mechanism of action and the potential of first and second-generation antipsychotics to exert effects on cellular processes that may be neuroprotective in schizophrenia is presented in this paper.

TL;DR: Pregnenolone may be a promising therapeutic agent for negative symptoms in patients with schizophrenia or schizoaffective disorder receiving stable doses of second-generation antipsychotics and merits further investigation for cognitive symptoms in schizophrenia.

TL;DR: Investigating neuroactive steroid levels in post-mortem brain tissue from subjects with schizophrenia, bipolar disorder, nonpsychotic depression, and control subjects to determine if neuroactive steroids are altered in these disorders found them to be candidate modulators of the pathophysiology of schizophrenia and bipolar disorder and relevant to the treatment of these disorders.